Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1121
Abstract: Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs). Both erlotinib and gefitinib, the two first‐generation EGFR‐TKIs, exhibit significant clinical responses for… read more here.
Keywords: egfr tkis; gefitinib; lung cancer; cancer ... See more keywords
Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31289
Abstract: Today, we know that approximately 30% of patients with non-small cell lung cancer (NSCLC) have targetable oncogenic mutations or gene rearrangements. In that context, it may be surprising to remember that prior to the identification… read more here.
Keywords: therapy; egfr tkis; generation; resistance ... See more keywords
Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Cancer"
DOI: 10.1002/ijc.34507
Abstract: EGFR exon 19 deletion (Del‐19) comprises multiple advanced NSCLC subtypes. EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 subtypes is unknown. We prospectively collected tissue samples from patients harboring NSCLC with Del‐19… read more here.
Keywords: t790m acquisition; del; egfr tkis; del subtypes ... See more keywords
Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.
Sign Up to like & getrecommendations! Published in 2021 at "Human cell"
DOI: 10.1007/s13577-021-00572-6
Abstract: Crosstalk between cancer cells and macrophages plays a crucial role in the development of cancer. In this study, our data showed that M1 macrophages attenuate, while M2 macrophages and tumor-associated macrophages enhance the EGFR-TKIs resistance… read more here.
Keywords: egfr tkis; nsclc cells; resistance; cancer ... See more keywords
USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.07.002
Abstract: As a newly discovered deubiquitinating enzyme, ubiquitin-specific protease 22 (USP22) is predictive of therapeutic outcomes in individual cancer patients. However, its clinical effects on malignancy and its roles in conferring resistance to EGFR-TKIs (epidermal growth… read more here.
Keywords: egfr; egfr mutant; resistance egfr; egfr tkis ... See more keywords
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.
Sign Up to like & getrecommendations! Published in 2017 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2017.07.003
Abstract: The therapeutic landscape of Non Small Lung Cancer (NSCLC) has been profoundly changed over the last decade with the clinical introduction of Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the discovery of… read more here.
Keywords: generation egfr; egfr mutated; egfr; egfr tkis ... See more keywords
Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.102820
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer (NSCLC) patients. Nonetheless, acquired resistance develops within 10-14 months and 20-30% of EGFR-mutated… read more here.
Keywords: egfr tkis; egfr mutated; combination egfr; tkis chemotherapy ... See more keywords
Hype or hope - Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC?
Sign Up to like & getrecommendations! Published in 2021 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2021.103454
Abstract: Three generations of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer (NSCLC) patients harboring EGFR-activating mutations, while a fourth generation is undergoing preclinical assessment.… read more here.
Keywords: advanced metastatic; combination; egfr tkis; resistance ... See more keywords
Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "Drug discovery today"
DOI: 10.1016/j.drudis.2017.10.004
Abstract: Epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, show excellent clinical efficacy for patients with non-small cell lung cancer (NSCLC) with EGFR mutations, including Exon 19 deletion and single-point substitution,… read more here.
Keywords: kinase inhibitors; egfr; egfr tkis; egfr tyrosine ... See more keywords
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.021
Abstract: INTRODUCTION Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could significantly prolong progression-free survival (PFS) than EGFR-TKI alone as first-line setting for patients with EGFR-mutant non-small-cell lung cancer (NSCLC).… read more here.
Keywords: egfr mutant; egfr tkis; tkis plus; patients egfr ... See more keywords
Risk of Treatment‐Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta‐analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR‐Mutated Non–Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.11.2236
Abstract: Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced EGFR‐mutated NSCLC. Estimating differences in toxicity between these EGFR TKIs is important for personalizing treatment. Methods We performed a meta‐analysis… read more here.
Keywords: gefitinib erlotinib; risk; egfr tkis; treatment ... See more keywords